We are investigating the Board of Directors of AmpliPhi Biosciences Corporation (NYSE: APHB) related to the sale of the Company to C3J Therapeutics, Inc. Under the terms of the proposed transaction, AmpliPhi stockholders will own 30% of AmpliPhi common stock upon completion of the transaction.